Work

Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)

Year: 2018

Type: article

Abstract: Introduction: ABT-165 is a first-in-class dual-variable domain immunoglobulin with specificity for both vascular endothelial growth factor and delta-like ligand 4 (DLL4) that has demonstrated encouraging preliminary clinical antitumor activity as monotherapy. As part of a phase 1 trial, we evaluated an expansion cohort of ABT-165 plus FOLFIRI in patients with 2L CRC previously treated with a fluoropyrimidine/oxaliplatin regimen with or without bevacizumab.

Source: Annals of Oncology

DOI: 10.1093/annonc/mdy151.233